CASI Pharmaceuticals (CASI) Competitors

Immunic (NASDAQ:IMUX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends.

Which has more risk and volatility, IMUX or CASI?

Immunic has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Does the media prefer IMUX or CASI?

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Immunic. MarketBeat recorded 6 mentions for CASI Pharmaceuticals and 5 mentions for Immunic. Immunic's average media sentiment score of 0.75 beat CASI Pharmaceuticals' score of -0.29 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend IMUX or CASI?

Immunic presently has a consensus price target of $13.20, suggesting a potential upside of 1,334.78%. CASI Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 108.33%. Given Immunic's stronger consensus rating and higher probable upside, research analysts clearly believe Immunic is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer IMUX or CASI?

CASI Pharmaceuticals received 90 more outperform votes than Immunic when rated by MarketBeat users. However, 65.50% of users gave Immunic an outperform vote while only 48.56% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Immunic	Outperform Votes 112 65.50%	Underperform Votes 59 34.50%
CASI Pharmaceuticals	Outperform Votes 202 48.56%	Underperform Votes 214 51.44%

Is IMUX or CASI more profitable?

Immunic has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. Immunic's return on equity of -169.55% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%

Which has stronger valuation & earnings, IMUX or CASI?

CASI Pharmaceuticals has higher revenue and earnings than Immunic. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61M	-$1.23	-0.75
CASI Pharmaceuticals	$28.54M	0.83	-$26.94M	-$2.55	-0.75

Do insiders & institutionals have more ownership in IMUX or CASI?

51.8% of Immunic shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 3.0% of Immunic shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immunic beats CASI Pharmaceuticals on 12 of the 18 factors compared between the two stocks.